Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
| 10.18 | |
| 10.41 | |
| - | |
| 10.44 | |
| 10.085 | |
| 9.02-14.57 | |
| 3 039 M | |
| 296 M | |
| 423 M | |
| -0.16 | |
| 0.711 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Investors in Amicus Therapeutics, Inc. FOLD need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 19, 2024 $3.00 Call had some of the highest im...
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. Inv...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
